Market Trends: With the oncology pipeline rapidly expanding in 2026, major pharmaceutical and biotechnology companies are forging large-scale partnerships. The limitations of existing treatments and the rising costs of new drug development are driving investor interest, with funding particularly focused on immunotherapy and cell therapy. ## Investment Timing: As the global economy recovers, the oncology diagnostics and therapeutics market is projected to grow by more than 10% compared to 2025. Companies believe that now is the optimal time to secure technology and gain market share. The accelerated regulatory approval processes in the United States and Europe are also contributing to expectations of early investment returns. ## Partnership Structure: The eight deals announced involve primarily joint research agreements and licensing agreements, with a mixed structure of upfront payments and milestone payments based on achievement of pre-defined goals. This structure is designed to allow both parties to share risks while also enabling them to receive high rewards upon success. ## Significance for Industry Innovation: The convergence of various technology platforms is leading to the rapid emergence of new drugs that are more targeted and have fewer side effects than existing cancer treatments. This represents an important turning point, providing patients with more treatment options and investors with new growth opportunities. ## Future Outlook: In the next 2-3 years, clinical data from Phase 2 or later is expected to be released for some of these partnerships. Successful clinical results are likely to lead to stock price increases and additional investment rounds for the companies involved.